<DOC>
	<DOC>NCT01098461</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging study evaluating the dose response, efficacy and safety of subcutaneously injected GSK716155 (albiglutide) in Japanese subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Dose Ranging Study of Albiglutide in Japanese Subjects</brief_title>
	<detailed_description>This is a Phase IIb, randomized, double-blind, placebo-controlled, multicenter, 4-parallel-group, dose ranging, superiority study evaluating the dose response, efficacy and safety of weekly and every other week subcutaneously injected GSK716155 (albiglutide) in subjects with type 2 diabetes mellitus.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Subject with a historical diagnosis of type 2 diabetes mellitus who is currently treated with diet and exercise only or one OAD BMI ≥18 kg/m2 and &lt;35 kg/m2 at Screening HbA1c between 7.0% and 10.0%, inclusive Fasting Cpeptide ≥0.8 ng/mL (≥0.26 nmol/L) Female subjects of childbearing potential must be practicing adequate contraception . Able and willing to monitor his/her own blood glucose concentrations with a home glucose monitor. Able and willing to provide written informed consent Diagnosis of type 1 diabetes mellitus Uncorrected thyroid dysfunction Previous use of insulin within one month prior to screening, or more than seven total days of insulin treatment within three months prior to screening Clinically significantly cardiovascular and/or cerebrovascular disease including, but not limited to the following: Previous history of stroke or transient ischemic attack Active, unstable coronary heart disease within the past six months before Screening Documented myocardial infarction within one year before Screening Any cardiac surgery including percutaneous transluminal coronary angioplasty, coronary stent placement, or coronary artery bypass graft surgery within one year before Screening Unstable angina Clinically significant arrhythmia or valvular heart disease Current heart failure NYHA class II to IV Resting systolic pressure &gt;160 mm Hg or diastolic pressure &gt;95 mm Hg at Screening ECG criteria at Screening Heart rate: &lt;40 and &gt;110 bpm PR interval: &lt;120 and &gt; 210 msec QRS interval: &lt;70 and &gt;120 msec QTc interval (Bazett): &gt;450 msec or &gt;480 msec with bundle branch block Fasting triglyceride level &gt;400 mg/dL at Screening AST or ALT &gt;2xULN, ALP and bilirubin &gt;1.5xULN (except known Gilbert's syndrome and a fractionated bilirubin that shows conjugated bilirubin &lt;35% of total bilirubin) If female, is currently lactating, within 6 weeks postpartum, pregnant, or actively trying to become pregnant Has significant renal disease as manifested by one or more of the following: Creatinine clearance at screening &lt;60 mL/min (calculated by CockcroftGault formula) at Screening Known loss of a kidney either by surgical ablation, injury or disease level A hemoglobinopathy that may affect determination of HbA1c level History of treated diabetic gastroparesis History of significant gastrointestinal surgery, including gastric bypass and banding, or surgeries thought to significantly affect upper gastrointestinal function Current ongoing symptomatic biliary disease or history of acute/chronic pancreatitis. Lipase and amylase at Screening &gt; ULN Severe diabetic neuropathy, preproliferative retinopathy or proliferative retinopathy, history of ketoacidosis or hyperosmolar coma History of cancer, other than squamous cell or basal cell carcinoma of the skin, that has not been in full remission for at least 3 years before Screening. (A history of treated cervical intraepithelial neoplasia I or cervical intraepithelial neoplasia II is allowed) Acute or chronic history of liver disease, positive hepatitis B surface antigen (HBsAg) or positive hepatitis C testing at Screening Current and history of alcohol or substance abuse Clinically significant anaemia or any other abnormal haematological profile that is considered by the investigator to be clinically significant Prior use of a GLP1 analog Known allergy to any formulation excipients, or Baker's yeast, or history of drug, or other allergy which, in the opinion of the responsible study physician, contradicts participation History of or family history of medullary carcinoma of the thyroid. History of or family history of multiple endocrine neoplasia type 2 Receipt of any investigational drug within the 12 weeks before Screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>dose-ranging</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>GSK716155</keyword>
	<keyword>Japan</keyword>
	<keyword>albiglutide</keyword>
</DOC>